anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain an antimicrobial composition containing water insoluble antimicrobial grains, a neutralized product of polyurethane urea polyamine, and a surfactant, having good dispersion stability and storage stability, having food feeling in use and useful for shampoo, etc. CONSTITUTION:The objective composition containing water insoluble antimicrobial grains (e.g. those of 2-mercaptopyridine-N-oxide polyvalent metal salt), a neutralized product of polyurethane urea polyamine, and surfactant (e.g. anion surfactant, amphoteric surfactant or nonionic surfactant). The dispersion system of the composition can be more stabilized by further blending a water soluble high polymer (e.g. starch derivative or cellulose derivative) therewith. The neutralized product of polyurethane urea polyamine is preferably a neutralized product by reacting an urethane prepolymer obtained by a reaction between a polyhydroxyl compound and a polyfunctional isocyanate with a polyalkylene polyamine.
All Veterans will receive a standard 6-session administration of Problem Solving Therapy (Nezu \& D'Zurilla, 1999). Session 1 will take place in-person during a scheduled appointment and will last for 1 hour. Subsequent sessions will take place over the telephone and will last for approximately 30 minutes. Participants in this arm will also receive the Moving Forward app for SmartPhones, which was adapted from Problem Solving Therapy to be used either as a standalone treatment or as an adjunct to other related therapies such as in-person Problem Solving Therapy or the Moving Forward website. The phone content matches Problem Solving Therapy. Benefits of the app include 24-hours accessibility of psychoeducational materials and worksheets.
NEW MATERIAL:The compound of formula I (R1 and R3 are H, lower alkyl, CF3, OH, lower alkoxy, amino, lower alkylamino, lower acylamino, lower alkoxymethyl, phenyl or pyridyl; R2 is H, lower alkyl, lower alkenyl, lower alkynyl, phenyl or pyridyl) and its salt. EXAMPLE:1,2-Dihydroxy-4,5,6-trimethyl-2-oxonicotinonitrile. USE:A cardiotonic agent free of side effect. Dose: 0.1-10mg/kg-weight daily in the case of oral administration. PREPARATION:The compound of formula I can be produced e.g. by reacting the compound of formula III with the compound of formula R2-X (X is halogen) (e.g. CH3I) in a solvent such as acetone in the presence of an alkali such as K2CO3, and reacting the resultant compound of formula IV with cyanoacetamide of formula V in a solvent such as ethanol in the presence of diethylamine, etc.
Cell-phones will be provided free of cost to participants who will be asked to text the bleeding dates of their menstruation and spotting every month within 3 days of the start of the bleeding. Study team will collaborate with a mobile phone company and the charge of SMS for reporting LMP dates will be free for the user. In situations, where the participant fails to text, she will be provided with several SMS reminders after the due date.
<P>PROBLEM TO BE SOLVED: To provide a method of selectively affecting angiogenic endothelial cells.  <P>SOLUTION: Angiogenic endothelial cells are selectively targeted with lipid/DNA complexes or cationic liposomes containing a substance which affects the targeted cells by inhibiting or promoting their growth. A site of angiogenesis can be precisely located by administering cationic liposomes containing a detectable label. The complexes may comprise nucleotide constructs comprising promoters which are selectively and exclusively activated in the environment of an angiogenic endothelial cell. The present invention can be used in the treatment of cancer, wound healing, and a variety of chronic inflammatory diseases.  <P>COPYRIGHT: (C)2011,JPO&INPIT
The present technology provides for a cell-synthesized biological thread, processes for making a cell-synthesized thread, and an apparatus for carrying out a process used to engineer the cell-synthesized thread. The thread is produced from living cells in culture and can be grown around the outer surface of a cylindrical bioreactor. The tissue comprising the thread has mechanical and biological properties achieved by altering the climactic conditions, stresses and strains on the tissue and chemical composition that prove beneficial in the medical industry. This process results in a biological thread that has high mechanical strength, decreased immunogenic effect and decreased thrombogenic effect when combined with other tissue. It also results in a product which can be used to create more complex constructs that otherwise could not have been generated. The threads can be used to make sutures, patches, and tubes, for example.
All CAI participants will complete the same intervention and will walk 6, 1-mile paths in the real wold (ie: around campus) with vibration feedback within 2 weeks of baseline assessment. A study team member will accompany each participant during each training.
Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the BCR-ABL tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in BCR-ABL positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients.

In vivo, imatinib inhibits tumor growth of BCR-ABL transfected murine myeloid cells as well as BCR-ABL positive leukemia lines derived from CML patients in blast crisis. 

Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-Kit, and inhibits PDGF- and SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in GIST cells, which express an activating c-Kit mutation.
Blood transfusion is a vital procedure, where transfusion-transmitted infection of hepatitis B virus (HBV) remains an important issue, especially from blood donors with occult hepatitis B virus infection (OBI). Occult hepatitis B virus infection is a complex entity to detect using surrogate blood biomarkers for intrahepatic viral transcriptional activity, requiring a continually refined battery of tests utilised for screening. This review aims to critically evaluate the latest advances in the current blood biomarkers to guide the identification of OBI donors and discuss novel HBV markers that could be introduced in future diagnostic practice. Challenges in detecting low HBV surface antigen levels, mutants, and complexes necessitate ultrasensitive multivalent dissociation assays, whilst HBV DNA testing requires improved sensitivity but worsens inaccessibility. Anti-core antibody assays defer almost all potentially infectious donations but have low specificity, and titres of anti-surface antibodies that prevent infectivity are poorly defined with suboptimal sensitivity. The challenges associated with these traditional blood HBV markers create an urgent need for alternative biomarkers that would help us better understand the OBI. Emerging viral biomarkers, such as pre-genomic RNA and HBV core-related antigen, immunological HBV biomarkers of T-cell reactivity and cytokine levels, and host biomarkers of microRNA and human leucocyte antigen molecules, present potential advances to gauge intrahepatic activity more accurately. Further studies on these markers may uncover an optimal diagnostic algorithm for OBI using quantification of various novel and traditional blood HBV markers. Addressing critical knowledge gaps identified in this review would decrease the residual risk of transfusion-transmitted HBV infection without compromising the sustainability of blood supplies.
Subjects will be reviewed and a blood sample will be taken for the measurement of HbA1c. Training on the use of DEXCOM G5 or similar will be provided by the research team. Competency on the use of the system will be evaluated. Participants will be advised to use real-time CGM continuously for the next 8 weeks. At the end of the first intervention, a blood sample for the measurement of HbA1c will be taken. Validated questionnaires evaluating diabetes-related distress, management and user acceptance will be completed.
Work Only participants were invited to attend the workplace throughout a 26-week intervention period. Participants in this group continued to provide mandatory urine samples and could earn base and performance pay. Work Only participants could work and earn base and performance pay independent of urinalysis results.
Provided is a kidney protective agent capable of protecting the kidney without lowering blood glucose level.　The kidney protective agent contains an active ingredient that is at least one R-3-hydroxybutyric acid ingredient selected from the group consisting of R-3-hydroxybutyric acid, a salt of R-3-hydroxybutyric acid and an alkyl ester of R-3-hydroxybutyric acid. The active ingredient may contain a salt of R-3-hydroxybutyric acid. The kidney protective agent may be a kidney protective agent capable of protecting the kidney without lowering blood glucose level. In particular, the kidney protective agent may be a kidney protective agent capable of protecting the kidney in nephropathy, such as diabetic nephropathy. The kidney protective agent may be a kidney protective agent capable of preventing an increase in kidney mass in diabetic nephropathy. The kidney protective agent may be a kidney protective agent capable of inhibiting the production of at least one selected from the group consisting of a chemokine ligand and an inflammatory cytokine in diabetic nephropathy.
Oral capecitabine 750mg/m2 b.i.d. days 1-14 and temozolomide 75mg/m2 b.i.d. days 10-14 every 28 day cycle, up to 8 cycles.
NEW MATERIAL:The compound of formula I (R<1> and R<2> are H, lower alkyl or lower alkenyl; R<3>-R<5> are H or lower alkyl; Y is H or lower acyl; m is 1 or 2; n is 0-2). EXAMPLE:3,3,5,5,8-Pentamethyl-1,7-nonadien-4-ol. USE:A perfumery component of perfumery composition. It has mossy top note accompanying green not like violet leaf, animalic and powderic perfume, and strong diffusibility and perfume-retainability, and harmonizes well with various other perfumery materials. It is useful also as a synthetic intermediate of the bicyclic alcohol of formula II and its ester with a lower aliphatic monocarboxylic acid. PREPARATION:The compound of formula I wherein Y is H can be prepared by reacting the oxygen-containing olefin of formula III (l is 0 or 1) with the organic magnesium compound of formula IV (X is halogen). The product can be converted another compound of formula I wherein Y is other than H by reacting with a lower aliphatic monocarboxylic acid.
Nitric oxide (NO) is a crucial gaseous signaling molecules in regulating cardiovascular, immune, and nervous systems. Controlled and targeted NO delivery is imperative for treating cancer, inflammation, and cardiovascular diseases. Despite various enzyme-prodrug therapy (EPT) systems facilitating controlled NO release, their clinical utility is hindered by nonspecific NO release and undesired metabolic consequence. In this study, a novel EPT system is presented utilizing a cellobioside-diazeniumdiolate (Cel2-NO) prodrug, activated by an endocellulase (Cel5A-h38) derived from the rumen uncultured bacterium of Hu sheep. This system demonstrates nearly complete orthogonality, wherein Cel2-NO prodrug maintains excellent stability under endogenous enzymes. Importantly, Cel5A-h38 efficiently processes the prodrug without recognizing endogenous glycosides. The targeted drug release capability of the system is vividly illustrated through an in vivo near-infrared imaging assay. The precise NO release by this EPT system exhibits significant therapeutic potential in a mouse hindlimb ischemia model, showcasing reductions in ischemic damage, ambulatory impairment, and modulation of inflammatory responses. Concurrently, the system enhances tissue repair and promotes function recovery efficacy. The novel EPT system holds broad applicability for the controlled and targeted delivery of essential drug molecules, providing a potent tool for treating cardiovascular diseases, tumors, and inflammation-related disorders.
This is a prospective, single center, pilot, open-label study of transplantation of hearts of HCVAb+ donors to HCVAb- recipients with subsequent therapy with sofosbuvir/velpatasvir (Epclusa®). Recipients of a heart from HCVAb+/NAT- donors is ARM 1 or the transmission-triggered arm of the study. In this arm, the study will monitor transmission of HCV by measuring HCV RNA in heart transplant recipients. If HCV RNA is detected, indicating transmission of HCV, recipients will be treated with sofosbuvir/velpatasvir (Epclusa®) for 12 weeks. Virological response will be assessed at 4 weeks, end of treatment and 12 weeks after completion of therapy.

Recipients of a heart from HCVAb+/NAT+ donors will be in ARM 2 or the prophylaxis arm of the study. In this arm, patients will be started on a 12-week course of sofosbuvir/velpatasvir (Epclusa®) on post-operative day 1 and will undergo close monitoring of HCV RNA for evidence of transmission as well as monitoring of adverse events from therapy.
The invention relates to a product for use in the therapeutic or prophylactic treatment of infections, said treatment comprising oral administration of the product, wherein the product is selected from a nutritional formulation, a food product, a dietary supplement, a beverage and a pharmaceutical product, said product containing carrot RG-I polysaccharides having the following combination features:a molecular weight in the range 10-300 kDa;a backbone consisting of galacturonic acid residues and rhamnose residues, said rhamnose residues being contained in alpha(1→4)-galacturonic-alpha(1→2)-rhamnose residues;the following monosaccharide composition:20-60 mol. % galacturonic acid residues, wherein the individual galacturonic acids can be methylated and/or acetyl-esterified;8-50 mol. % rhamnose residues;0-40 mol. % arabinose residues;0-40 mol. % galactose residues;molar ratio of galacturonic acid residues to rhamnose residues in the range of 5:1 to 1:1;galacturonic acid residues, rhamnose residues, arabinose residues and galactose residues together constitute at least 85 mol. % of the monosaccharide residues in the carrot RG-I polysaccharides.These carrot RG-I polysaccharides can be produced by partially hydrolysing pectic polysaccharides present in a carrot pectin isolate. The effectiveness of carrot RG-I polysaccharides against infections is substantially improved by enzymatically hydrolysing the RG-I polysaccharides to remove at least part of the homogalacturonan component.
PURPOSE: Respiratory-swallow coordination (RSC) frequently changes in people with Parkinson's disease (PwPD). Little is known about how these changes relate to impairments in swallowing safety (penetration and aspiration) and efficiency (pharyngeal residue). Therefore, the aims of this study were to assess the relationships between RSC, pharyngeal residue, penetration, and aspiration in PwPD.
METHOD: Twenty-four PwPD were recruited to undergo simultaneous assessment of RSC, swallowing safety, and swallowing efficiency. RSC was assessed using respiratory inductive plethysmography and nasal airflow and included measurements of respiratory pause duration, respiratory phase patterning, and lung volume during swallowing. Swallowing safety and efficiency were assessed using flexible endoscopic evaluation of swallowing, analyzed using the Visual Analysis of Swallowing Efficiency and Safety, and included measurements of pharyngeal residue, penetration, and aspiration. All data were blindly analyzed, with 20% of the data repeated for interrater reliability assessment. Multilevel statistical models were used to examine the relationships between RSC and swallowing.
RESULTS: A total of 812 swallows were analyzed from 24 participants. Only 33.4% of swallows exhibited the typical exhale-swallow-exhale pattern. Additionally, 95% of participants exhibited abnormal swallow function. More severe hypopharyngeal residue ratings were associated with inhaling before the swallow compared to exhaling before the swallow. Additionally, more severe events of penetration and aspiration were associated with (a) inhaling before the swallow compared to exhaling before the swallow, (b) inhaling after the swallow compared to exhaling after the swallow, and (c) longer swallow-related respiratory pause durations. Inhaling after the swallow exhibited the strongest relationship with impairments in swallowing safety when compared to all other RSC variables.
CONCLUSIONS: RSC exhibited significant relationships with pharyngeal residue, penetration, and aspiration in these PwPD. Clinicians should attend to RSC when assessing swallowing in PwPD. Future research is needed to examine if training an exhale-swallow-exhale pattern can be used to improve disordered swallowing in PwPD.
OPEN SCIENCE FORM: https://doi.org/10.23641/asha.27211770.
The 150-mg vismodegib drug product is a hard gelatin capsule formulation for oral administration. This study involves one year of treatment with Erivedge (150 mg/day) plus two years of follow-up.
Participants will undergo a 18F-fluciclovine PET scan at the time of their SRS planning magnetic resonance imaging (MRI). Then participants will undergo single-fraction SRS as standard of care (SOC). A second 18F-fluciclovine PET scan will be completed 8 weeks (± 2 weeks) after SRS.
The invention relates to compositions comprising; RNA molecules encoding for a RNA polymerase complex region from an RNA virus and a protein antigen and lipid nanoparticles, characterised as having a z-average diameter particle size of 20 – 80 nm, the nanoparticles comprise a surface comprising cationic lipids and a hydrophobic core, the hydrophobic core comprises liquid oil, wherein lipids present are in a liquid phase at 25˚C and the RNA molecules are complexed to the cationic lipids to form RNA molecules-lipid nanoparticle complexes. Optionally the protein antigen is derived from a RNA virus such as, HIV, a coronavirus e.g. MERS, SARS, SARS-CoV-2, Venezuelan equine encephalitis (VEE) or Zika virus. Alternatively the antigen is derived from cancer or a bacterium. The composition further comprises a hydrophobic surfactant selected from sorbitan monostearate, sorbitan monooleate or sorbitan trioleate and hydrophilic surfactant comprising polyethylene oxide or polysorbate. The cationic lipid preferably comprises DOTAP. The hydrophobic core can comprise a solid inorganic nanoparticle, selected from metal salts, metal oxides, metal hydroxides or metal phosphates. The liquid oil comprises vegetable, animal or synthetic oil. Methods of using these particles for treatment and vaccination are also disclosed.
Dextroamphetamine Saccharate, Amphetamine Asparate Monohydrate, Dextroamphetamine Sulfate and, Amphetamine Sulfate Extended-Release Capsules is a once daily extended-release, single-entity amphetamine product. Dextroamphetamine Saccharate, Amphetamine Asparate Monohydrate, Dextroamphetamine Sulfate and, Amphetamine Sulfate Extended-Release Capsules combines the neutral sulfate salts of dextroamphetamine and amphetamine, with the dextro isomer of amphetamine saccharate and d,l-amphetamine aspartate monohydrate. The Dextroamphetamine Saccharate, Amphetamine Asparate Monohydrate, Dextroamphetamine Sulfate and, Amphetamine Sulfate Extended-Release Capsules® capsule contains two types of drug-containing beads designed to give a double-pulsed delivery of amphetamines, which prolongs the release of amphetamine from Dextroamphetamine Saccharate, Amphetamine Asparate Monohydrate, Dextroamphetamine Sulfate and, Amphetamine Sulfate Extended-Release Capsules compared to the conventional ADDERALL® (immediate-release) tablet formulation. 

Inactive Ingredients and Colors: The inactive ingredients in Dextroamphetamine Saccharate, Amphetamine Asparate Monohydrate, Dextroamphetamine Sulfate and, Amphetamine Sulfate Extended-Release Capsules capsules include: gelatin capsules, hydroxypropyl methylcellulose, methacrylic acid copolymer, opadry beige, sugar spheres, talc, and triethyl citrate. Gelatin capsules contain edible inks, kosher gelatin, and titanium dioxide. The 5 mg, 10 mg, and 15 mg capsules also contain FD&C Blue #2. The 20 mg, 25 mg, and 30 mg capsules also contain red iron oxide and yellow iron oxide.
Background Pain is a complication in patients with transfusion-dependent thalassemia (TDT). There are several mechanisms underlying pain in people with thalassemia and low hemoglobin at the end of the transfusion cycle was the most etiology. Pain can develop into chronic pain and interfere with the quality of life. The Brief Pain Inventory Short Form (BPI-SF) can help identify pain in people with TDT. The present study aimed to compare pain before and after transfusion in adult TDT patients. Methods It was an analytical observational study using a cross-sectional design on adult TDT patients with pain who came to the Haemato-Oncology Clinic of Dr. Hasan Sadikin Hospital Bandung. This study was conducted from December 2020 to July 2021. All subjects were assisted in filling out the Indonesian version of the BPI-SF questionnaire hemoglobin levels were examined and before and after transfusion, then paired test analysis was performed using the Wilcoxon Test. Results This study is conducted on 60 adult TDT patients with symptoms of pain. The median value of pain intensity and pain interferes with life obtained from the Indonesian version of the BPI-SF score after transfusion decreased significantly compared to before transfusion (NRS 5 vs. 0 and 2.8 vs. 0; p=0.0001). Conclusion There is a significant difference in pain intensity and pain interfere with life in adults with TDT before and after transfusion. It is necessary to carry out pain assessments for thalassemia patients.
Chrononutrition is a nutritional regimen that follows our biological clock, marked by the changes in metabolism that occur during the day. This regimen includes the distribution of energy, the regularity and frequency of meals, and the importance of these factors for metabolic health. A growing body of animal and human evidence indicates that the timing of food intake throughout the day can have a significant and beneficial impact on the metabolic health and well-being of individuals. In particular, both the timing and frequency of meals have been associated with obesity, type 2 diabetes mellitus (T2DM), cardiovascular disease, and other chronic conditions. Today's busy lifestyle makes many people skip breakfast and eat late at night. Eating late at night has been shown to cause a circadian misalignment, with the latter having a negative impact on weight control and glucose metabolism. Additionally, some studies have found a relatively strong association between skipping breakfast and insulin resistance, and T2DM. Against the backdrop of escalating obesity and T2DM rates, coupled with the recognized influence of food timing on disease evolution and control, this review aimed to synthesize insights from epidemiological and intervention studies of the interplay of timing of food intake and macronutrient consumption, reporting their impact on obesity and T2DM.
Activity-based probes, which are specific for certain active cysteine proteases (caspase, cathepsin and legumain) and carry radioactive labels, are disclosed. The present probes comprise an acyloxymethyketone (AOMK) “warhead” that binds only to active enzyme. The probes further comprise peptide-like structure that targets the probe to a specific cysteine protease or protease family, and a radiolabel on the probe, which is bound to the targeted enzyme. It has been found that the present probes are stable in vivo and give specific target images distinguishable over background. The preferred probes are labeled with a positron-emitting agent such as  64 Cu,  125 I (SPECT) and  99m Tc (PET). The probes show in vivo half-life and stability well suited for imaging.